Cargando…

Targeting CD10 on B-Cell Leukemia Using the Universal CAR T-Cell Platform (UniCAR)

Chimeric antigen receptor (CAR)-expressing T-cells are without a doubt a breakthrough therapy for hematological malignancies. Despite their success, clinical experience has revealed several challenges, which include relapse after targeting single antigens such as CD19 in the case of B-cell acute lym...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitwasi, Nicola, Arndt, Claudia, Loureiro, Liliana R., Kegler, Alexandra, Fasslrinner, Frederick, Berndt, Nicole, Bergmann, Ralf, Hořejší, Vaclav, Rössig, Claudia, Bachmann, Michael, Feldmann, Anja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105388/ https://www.ncbi.nlm.nih.gov/pubmed/35563312 http://dx.doi.org/10.3390/ijms23094920

Ejemplares similares

UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells
por: Arndt, Claudia, et al.
Publicado: (2020)

T cells engrafted with a UniCAR 28/z outperform UniCAR BB/z-transduced T cells in the face of regulatory T cell-mediated immunosuppression
por: Kegler, Alexandra, et al.
Publicado: (2019)

Highly Efficient Targeting of EGFR-Expressing Tumor Cells with UniCAR T Cells via Target Modules Based on Cetuximab(®)
por: Jureczek, Justyna, et al.
Publicado: (2020)

Development of novel target modules for retargeting of UniCAR T cells to GD2 positive tumor cells
por: Mitwasi, Nicola, et al.
Publicado: (2017)

Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers
por: Loureiro, Liliana R., et al.
Publicado: (2020)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
por: Jureczek, Justyna, et al.
Publicado: (2019)

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR
por: Arndt, Claudia, et al.
Publicado: (2019)

Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells
por: Loureiro, L. R., et al.
Publicado: (2018)

From mono- to bivalent: improving theranostic properties of target modules for redirection of UniCAR T cells against EGFR-expressing tumor cells in vitro and in vivo
por: Albert, Susann, et al.
Publicado: (2018)

Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells
por: Bachmann, Dominik, et al.
Publicado: (2017)

Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR”
por: Feldmann, Anja, et al.
Publicado: (2017)

Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
por: Arndt, Claudia, et al.
Publicado: (2020)

Targeting Acute Myeloid Leukemia Using the RevCAR Platform: A Programmable, Switchable and Combinatorial Strategy
por: Kittel-Boselli, Enrico, et al.
Publicado: (2021)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML
por: Meyer, Jan-Erik, et al.
Publicado: (2021)

Anti-CAR-engineered T cells for epitope-based elimination of autologous CAR T cells
por: Koristka, Stefanie, et al.
Publicado: (2019)

Specific and safe targeting of glioblastoma using switchable and logic-gated RevCAR T cells
por: Saleh, Haidy A., et al.
Publicado: (2023)

Combining Radiation- with Immunotherapy in Prostate Cancer: Influence of Radiation on T Cells
por: Lindner, Diana, et al.
Publicado: (2022)

Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy
por: Feldmann, Anja, et al.
Publicado: (2020)

Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management
por: Arndt, Claudia, et al.
Publicado: (2022)

Carbohydrate Targets for CAR T Cells in Solid Childhood Cancers
por: Rossig, Claudia, et al.
Publicado: (2018)

Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers
por: Kailayangiri, Sareetha, et al.
Publicado: (2020)

S79. CAR strategies in solid tumours
por: Rossig, C
Publicado: (2014)

A Small Step, a Giant Leap: Somatic Hypermutation of a Single Amino Acid Leads to Anti-La Autoreactivity
por: Bartsch, Tabea, et al.
Publicado: (2021)

Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
por: Cartellieri, M, et al.
Publicado: (2016)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
por: Loff, Simon, et al.
Publicado: (2020)

Validation of CD98hc as a Therapeutic Target for a Combination of Radiation and Immunotherapies in Head and Neck Squamous Cell Carcinoma
por: Köseer, Ayşe Sedef, et al.
Publicado: (2022)

Two Be or Not Two Be: The Nuclear Autoantigen La/SS-B Is Able to Form Dimers and Oligomers in a Redox Dependent Manner
por: Berndt, Nicole, et al.
Publicado: (2021)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

A novel ACE2 decoy for both neutralization of SARS-CoV-2 variants and killing of infected cells
por: Kegler, Alexandra, et al.
Publicado: (2023)

And Yet It Moves: Oxidation of the Nuclear Autoantigen La/SS-B Is the Driving Force for Nucleo-Cytoplasmic Shuttling
por: Berndt, Nicole, et al.
Publicado: (2021)

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies
por: Kyriakidis, Ioannis, et al.
Publicado: (2021)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro
por: Liu, Maoxuan, et al.
Publicado: (2022)

Activation-inducible CAR expression enables precise control over engineered CAR T cell function
por: Fraessle, Simon P., et al.
Publicado: (2023)

CARs and Drugs: Pharmacological Ways of Boosting CAR-T-Cell Therapy
por: Harrer, Dennis Christoph, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_f9tdn8s30v04ihlspq9shbgln2